[Acinetobacter, a nosocomial pathogen. Contribution of experimental models]
- PMID: 11995384
[Acinetobacter, a nosocomial pathogen. Contribution of experimental models]
Abstract
Epidemiology: The increasing importance of Acinetobacter as a nosocomial pathogen responsible for outbreaks in intensive care units has been pointed out for twenty years. Today Acinetobacter infections are essentially pneumonia in patients under mechanical ventilation.
Experimental models: Most clinical isolates are resistant to b-lactam antibiotics as well as to other drugs. Animal models represent an essential step between in vivo testing an<d clinical studies, necessary to understand physiopathology, pharmacology and efficacy of therapy. The virulence of clinical isolates of Acinetobacter spp has been studied in a mouse model of systemic infection. Pharmacological studies and efficacy of antibiotics have been studied in a mouse model of Acinetobacter pneumonia.
Human therapeutics: The majority of strains are multi-resistant to antibiotics and the infections they cause are difficult to treat. Isolated or combined Sulbactam has often been used with success.
Similar articles
-
Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients.Chest. 1999 May;115(5):1378-82. doi: 10.1378/chest.115.5.1378. Chest. 1999. PMID: 10334156
-
The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents.J Hosp Infect. 1995 Jun;30 Suppl:441-52. doi: 10.1016/0195-6701(95)90048-9. J Hosp Infect. 1995. PMID: 7560983
-
Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors.Scand J Infect Dis. 2010 Oct;42(10):741-6. doi: 10.3109/00365548.2010.489568. Scand J Infect Dis. 2010. PMID: 20500117
-
Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.Ann Pharmacother. 2004 Sep;38(9):1449-59. doi: 10.1345/aph.1D592. Epub 2004 Jul 27. Ann Pharmacother. 2004. PMID: 15280512 Review.
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous